Adicet Bio Grants Inducement Awards to Attract Talent for Innovative Therapies

Adicet Bio Expands Talent Pool with New Inducement Award

Adicet Bio, Inc., a clinical-stage biotechnology company specializing in allogeneic gamma delta T cell therapies, announces a significant inducement award to attract new talent. On November 29, 2024, the company grants non-qualified stock options to a new employee, allowing the purchase of 6,000 shares of common stock at an exercise price of $1.13 per share. This move is in line with Adicet’s strategic approach to enhance its research capabilities and innovation in developing therapies for autoimmune diseases and cancer. The vesting schedule for the options reflects a commitment to employee retention, with one-fourth of the options vesting after the first year and the remaining three-fourths vesting over the next three years, contingent upon continued employment.

The inducement award is part of Adicet's 2022 Inducement Plan, which aims to attract skilled professionals in the competitive biotech landscape. The plan was adopted in January 2022 and later amended in January 2023, demonstrating the company's proactive measures to refine its talent acquisition strategies. Authorized by an independent compensation committee, this award aligns with Nasdaq Listing Rule 5635(c)(4), highlighting Adicet's adherence to corporate governance standards while fostering a motivated workforce. By incentivizing new hires with stock options, Adicet positions itself to cultivate a dedicated team focused on advancing its innovative therapies.

Adicet Bio continues to pioneer the development of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) to provide sustained therapeutic activity in patients. This strategic focus on groundbreaking therapies underscores the company’s commitment to addressing serious health conditions through innovative solutions. By investing in talent and fostering a collaborative work environment, Adicet aims to enhance its research and development efforts, ultimately leading to transformative treatments in the field of immunotherapy.

In addition to the inducement award, Adicet Bio invites interested parties to explore further details about its innovative therapies on its official website. The company's ongoing efforts to attract top-tier talent play a crucial role in its mission to revolutionize treatment options for challenging medical conditions, ensuring that it remains at the forefront of the biotechnology industry.